|
|
|
|
Office Locations:
|
1000 Wilson Blvd., Suite 3000
Arlington, VA 22209
Phone: 703-562-4000
| | |
|
|
|
|
Consumer Products & Services
Information Technology
Life Sciences & Healthcare
|
|
|
Sands Capital Ventures invests in promising businesses in three dynamic, high-growth markets: Life Sciences, Technology, and Global Consumer. The firm is the venture capital affiliate of Sands Capital Management, an investment firm founded in 1992 that manages long-only, concentrated public company portfolios. An independent, staff-owned firm based in the Greater Washington, DC area, Sands Capital managed more than $52 billion* in client assets as of December 31, 2023. Sands' Private Growth strategy targets growth equity investments in highly innovative, mid-late stage technology companies. The firm typically seeks a $25 million to $100 million target investment size per company.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
|
| Name | |
| |
Title | |
Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
|
| Christy Steele | |
| |
Senior Associate | |
| Erin Soule | |
CPA | |
Director of Finance and Operations | |
| Frank Sands | |
CFA | |
CIO and CEO & Co-Founder | |
| Gene Riechers | |
| |
Venture Partner | |
| Ian Ratcliffe | |
| |
Managing Partner | |
|
|
|
Date
|
Name
|
State
|
Amount
|
Stage
|
12/17/2025
|
Codoxo
|
GA
|
$35,000,000
|
Series C
|
12/15/2025
|
PolyAI
|
NY
|
$86,000,000
|
Series D
|
12/10/2025
|
Impulse Dynamics
|
NJ
|
$158,000,000
|
|
11/06/2025
|
Elephas Biosciences
|
WI
|
$40,000,000
|
Series B-2
|
09/22/2025
|
Avenzo Therapeutics
|
CA
|
$60,000,000
|
Series B
|
06/24/2025
|
Chronicle Studios
|
CA
|
$11,600,000
|
Seed
|
06/23/2025
|
RAMP
|
MA
|
$200,000,000
|
Series E
|
06/17/2025
|
Ramp Business
|
NY
|
$200,000,000
|
Series E
|
06/02/2025
|
SpyGlass Pharma
|
CA
|
$75,000,000
|
Series D
|
03/13/2025
|
Flock Safety
|
GA
|
$275,000,000
|
Venture
|
03/11/2025
|
pgEdge
|
VA
|
undisclosed
|
Seed
|
02/27/2025
|
CompScience
|
CA
|
$27,600,000
|
Series B
|
|
|
|
|
|
|
|
